Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HY035 Cell Injection in CD7-positive Relapsed or Refractory Hematologic Malignancies
NCT07784309Phase 1Enrolling by invitation
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Aug 2026
- Primary completion
- Jun 2029
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HY035 in t-cell acute lymphoblastic leukemia (T-ALL), lymphoblastic lymphoma (LL), acute myeloid leukemia (AML) and 1 more, sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Composite Complete Remission Rate and Overall Remission Rate at 3 months. Started Aug 2026; status: enrolling by invitation.
02
Drugs
HY035
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)lymphoblastic lymphoma (LL)acute myeloid leukemia (AML)T-cell lymphoma
Beyond the preview
Go deeper on NCT07784309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07784309.